临床II期非小细胞肺癌:我们可以"只是给予辅助疗法"吗?
Rajika Jindani1, Isaac Loh1, Jorge Humberto Rodriguez-Quintero1
1Department of Cardiothoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.
Journal of thoracic disease
|January 12, 2026
概括
辅助治疗改善了手术后临床II期非小细胞肺癌 (NSCLC) 患者的生存率. 然而,只有不到60%的符合条件的患者接受这种关键治疗,这会影响整体存活率.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 癌症治疗方法 癌症治疗方法
背景情况:
- 多模式治疗的进步改变了临床II期 (cII) 非小细胞肺癌 (NSCLC) 治疗.
- 对cII NSCLC治疗的最佳顺序仍然是一个重要的临床问题.
- 调查前期手术后的辅助疗法吸收和结果至关重要.
研究的目的:
- 为了确定在手术切除后患有cII NSCLC的患者中辅助疗法 (AT) 吸收的预测因素.
- 评估临床分期的准确性及其对治疗决策的影响.
- 评估与AT接收相关的瘤结局,包括总生存期 (OS).
主要方法:
- 从2015-2019年对国家癌症数据库 (NCDB) 的回顾性分析.
- 包括经过手术切除的cII NSCLC患者.
- 按AT接收进行分层,分析吸收,病理阶段和OS,使用Cox回归和Kaplan-Meier曲线在倾向-得分匹配的队列中.
主要成果:
- 17,674名患有cII NSCLC的患者接受了手术,95.9%的患者进行了前置手术.
- 50.9%的前期手术患者接受了AT; 23.3%的患者经历了病理升级.
- 只有58.4%的患有病理II-IV期疾病的患者接受了AT.
- 较低的AT吸收与年龄较大,并发症和公共保险有关.
- 在匹配的队列中,AT接收改善了5年的OS (62.2%与52.2%,P<0.001).
结论:
- 尽管有迹象表明,不到60%的符合条件的cII NSCLC患者接受AT.
- 没有接受AT与更糟糕的生存率有关,特别是在升级阶段的患者中.
- 需要制定改善AT完成或采用新辅助疗法的策略.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.